CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0442 (clinicaltrials.gov NCT No: NCT01421667)
Title:A phase 2 study of brentuximab vedotin (SGN-35) in relapsed or refractory non-Hodgkin lymphoma (NHL)
Principal Investigator:Yasuhiro Oki
Treatment Agent:SGN-35
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if brentuximab vedotin can
have an effect on non-Hodgkin lymphoma that is either refractory or recurrent
or diffuse large B-cell lymphoma with low levels of CD30 that cannot be seen
using traditional methods. The side effects of brentuximab vedotin will also be
studied.

The study is also being done to test if brentuximab vedotin given together with
another drug called rituximab has an effect on cancer in patients with
non-Hodgkin lymphoma that is either refractory or recurrent or diffuse large
B-cell lymphoma. The side effects of brentuximab vedotin and rituximab will
also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:SGN-35
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults